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Abstract
Background: Thrombolytic therapy is effective in selected patients with deep vein thrombosis (DVT). Therefore,
identification of a marker that reflects the age of thrombus is of particular concern. This pilot study aimed to
identify a marker that reflects the time after onset in human aspirated DVT.
Methods: We histologically and immunohistochemically analyzed 16 aspirated thrombi. The times from onset to
aspiration ranged from 5 to 60 days (median of 13 days). Paraffin sections were stained with hematoxylin and
eosin and antibodies for fibrin, glycophorin A, integrin α2bβ3, macrophage markers (CD68, CD163, and CD206),
CD34, and smooth muscle actin (SMA).
Results: All thrombi were immunopositive for glycophorin A, fibrin, integrin α2bβ3, CD68, CD163, and CD206, and
contained granulocytes. Almost all of the thrombi had small foci of CD34- or SMA-immunopositive areas. CD68- and
CD163-immunopositive cell numbers were positively correlated with the time after onset, while the glycophorin
A-immunopositive area was negatively correlated with the time after onset. In double immunohistochemistry, CD163-
positive cells existed predominantly among the CD68-immunopositive macrophage population. CD163-positive
macrophages were closely localized with glycophorin A, CD34, or SMA-positive cell-rich areas.
Conclusions: These findings indicate that CD163 macrophage and erythrocyte contents could be markers for
evaluation of the age of thrombus in DVT. Additionally, CD163 macrophages might play a role in organization of the
process of venous thrombus.
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Background
Venous thromboembolisms are a global health problem.
The annual incidence of venous thromboembolism
ranges from 0.75 to 2.69 per 1000 individuals in Western
Europe, North America, Australia, and Argentina. This
incidence has recently increased to between 2 and 7 per
1000 among those aged 70 years or older [1]. In a series
of 140 cases of fatal pulmonary embolisms, the emboli
originated in the iliac veins (4.5%), femoral veins
(20.7%), and deep crural veins (74.8%) [2]. The patho-
logical findings of venous thrombus vary with the time
after onset. Pathological findings include platelet ag-
gregation and fibrin formation with erythrocytes and
neutrophils, lysis of cellular components, endothelial
reactions and fibroblast proliferation, and replacement
of thrombi with fibrous tissue and formation of reca-
nalized vessels. Findings of deep vein thrombosis
(DVT) have been obtained from pathological and fo-
rensic examinations, and are affected by degenerative
changes at postmortem, therapeutic effects, and circu-
latory disturbance in the agonal stage.
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Thrombolytic therapy can be more effective in selected
patients with DVT compared with anticoagulant treat-
ment alone [3, 4]. Addition of catheter-directed thromb-
olysis in conventional anticoagulant treatment for acute
DVT reduces the risk of post-thrombotic syndrome by
14% at a 2-year follow-up and 28% at a 5-year follow up
[5, 6]. Thrombolytic therapy results in a substantial in-
crease in the risk of bleeding. Therefore, identification
of a marker that reflects the age of thrombus is of par-
ticular concern. Alternatively activated macrophages
are related to resolution of inflammation, tissue repair,
and angiogenesis [7]. Therefore, we hypothesize that
alternatively activated macrophages reflect the age of
thrombus, as well as endothelial and fibroblastic
proliferation.
Aspiration thrombectomy has been used to restore vas-
cular patency alone and in conjunction with thrombolytic
agents [8]. For treatment of acute DVT, aspiration
thrombectomy with or without stenting is superior to
anticoagulant therapy alone in terms of ensuring venous
patency and improving clinical symptoms [9]. Techno-
logical advances have allowed evaluation the pathological
changes in culprit thrombi in patients with DVT.
This pilot study aimed to determine the cellular and
molecular components, and to identify a marker that re-
flects the time after onset in human aspirated DVT.
Methods
Aspirated thrombi from patients with DVT
The ethics committee of the Miyazaki University ap-
proved the study protocol (approval no. 427). We ob-
tained informed consent from the patients with DVT.
Sixteen thrombi were obtained from 16 patients (8 men
and 8 women; age range, 35–78 years) with DVT who
were diagnosed based on clinical symptoms, laboratory
data, and clinical imaging findings. The thrombi were
mainly aspirated from the proximal portion of the
thrombi with a guiding catheter (Guider Softip Guiding
Catheter; Boston Scientific Japan, Tokyo, Japan). This
catheter was placed from the popliteal vein to the iliac
vein (10 cases), the leg vein to the inferior vena cava
(5), and the subclavian vein to the superior vena cava
(1). X-ray venography showed an extensive filling defect
in the femoral vein before thrombus aspiration and re-
duction of the filling defect after thrombus aspiration
(Fig. 1). An additional movie file shows this in more
detail (see Additional file 1). We estimated the time of
onset based on clinical symptoms and a medical inter-
view. The times from onset to aspiration varied from 5
to 60 days, with a median of 13 days. The underlying dis-
eases of the patients included the following: trauma and
long-term immobilization (n = 5), idiopathic (n = 3), ma-
lignant tumor postoperatively (n = 2), chronic inflam-
matory disease (n = 2), Budd–Chiari syndrome (n = 1),
chronic renal failure (n = 1), peripheral artery disease
(n = 1), and gynecologic surgery (n = 1). Thirteen of 16
patients were intravenously administered heparin for 1
to 30 days, and six of 16 patients were intravenously
administered thrombolytic agents for 1 to 12 days be-
fore thrombus aspiration.
All aspirated thrombi were immediately fixed in 4%
paraformaldehyde and embedded in paraffin for histo-
logical evaluation. Sections (4-μm thick) were stained with
hematoxylin and eosin and morphologically assessed. Con-
secutive sections were immunohistochemically analyzed.
Immunohistochemistry
Consecutive 4-μm slices were immunohistochemically
stained using antibodies against α-smooth muscle actin
(SMA) (mouse monoclonal, clone 1A4; Dako, Glostrup,
Denmark), CD34 (mouse monoclonal, QBEnd 10; Dako),
CD68 (mouse monoclonal, clone PGM-1; Dako), CD163,
a macrophage scavenger receptor (mouse monoclonal,
clone 10D6; Leica Microsystems, Newcastle upon Tyne,
UK), CD206, mannose receptor C type 1 (mouse mono-
clonal, clone 5C11; LifeSpan Biosciences, Inc., Seattle,
WA, USA), fibrin (mouse monoclonal, clone T2G1;
Accurate Chemical & Scientific Corp., Westbury, NY,
USA), glycophorin A (mouse monoclonal, clone JC159;
Dako), and platelet integrin α2bβ3 (sheep polyclonal;
Affinity Biologicals Inc., Hamilton, CA, USA). The
Fig. 1 Representative images of X-ray venography before and after
thrombus aspiration. X-ray venography shows an extensive filling
defect before thrombus aspiration along the femoral vein, and a
considerable reduction in the defect after thrombus aspiration
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sections were stained with Envision (DAKO) or donkey
anti-sheep IgG secondary antibody (Jackson ImmunoRe-
search, Baltimore, MA, USA). Horseradish peroxidase
activity was visualized using 3, 3′-diaminobenzidine tet-
rahydrochloride. The immunostaining controls included
non-immune mouse or sheep IgG instead of primary
antibodies.
We performed double immunohistochemical staining
for CD163 (rabbit polyclonal; DB Biotech, Kosice,
Slovakia) and CD68 (Dako), CD163 (DB Biotech) and
CD34 (Dako), CD163 (DB Biotech) and glycophorin A
(Dako), and CD163 (DB Biotech) and SMA (Dako) using
the MACH2 Double Stain kit (Biocare Medical, Concord,
CA, USA).
Quantitative methods
The sizes of the thrombi were measured in sections
under a microscope using the NIS-Element-D 3.2 image
analysis software (Nikon, Tokyo, Japan). Areas that were
immunopositive for CD34, fibrin, integrin α2bβ3, glyco-
phorin A, and SMA were semiquantified using the Win
Roof color image analysis software (Mitani, Fukui, Japan)
(Fig. 2) [10]. These areas are expressed as the ratios of
positively stained areas per thrombus area. The number
of granulocytes without lytic change was counted in the
five most cellular fields under a 20× objective lens, and
is expressed as the number per mm2. The immunopo-
sitive cell numbers for CD68, CD163, and CD206 in
venous thrombi were counted in the five most heavily
stained fields under a 20× objective lens. Cell density
is expressed as the number of immunopositive cells
per mm2.
Statistical analysis
All data are presented as medians and interquartile
ranges. Differences between individual groups were
tested using the Kruskal–Wallis test with Dunn’s mul-
tiple comparison tests (GraphPad Prizm 6; GraphPad
Software Inc., San Diego, CA, USA). The relationships
between factors were evaluated using Spearman’s rank
correlation coefficients. Values of P < 0.05 were consid-
ered significant.
Results
Macro- and microscopic findings from aspirated
venous thrombi
The aspirated thrombi were red or mixed red and white
(Fig. 3a). The thrombi were composed of erythrocyte-
rich areas, eosinophilic granular or fibrinous areas, and
granulocytes or mononuclear leukocytes (Fig. 3b).
Neutrophils were mainly accumulated at the border of
erythrocyte-rich areas and eosinophilic granular or
fibrinous areas (Fig. 3b). The thrombi showed various
degrees of cell lytic change (Fig. 3c) and infiltration of
macrophage-like cells in part (Fig. 3d). One half of the
thrombi focally exhibited organizing reactions with
infiltration of mononuclear leukocytes (Fig. 3e).
Immunohistochemical findings from aspirated thrombi
All venous thrombi were immunopositive for glycophorin
A, platelet integrin α2bβ3, and fibrin (Fig. 4, Table 1).
Among them, glycophorin A- (p < 0.0001) and fibrin-
immunopositive areas (p < 0.01) were larger than those of
the integrin α2bβ3-immunopositive area (Table 1). The
thrombi had small foci of CD34- and SMA-
immunopositive areas (Table 1). Flat CD34-positive
cells covered the surface of thrombi and formed micro-
vessels. CD34 and SMA-immunopositive areas were
positively correlated (r = 0.73, p < 0.01). There were
CD68- and CD163-immunopositive mononuclear cells
and stellate cells in all thrombi. The numbers of CD68-
(p < 0.01) and CD163-positive cells (p < 0.0001) were
significantly greater than those of the CD206-positive
cells (Table 1). Immunopositive areas and cell numbers
Fig. 2 Representative immunohistochemical image of glycophorin
A and its color-extracted image in image analysis. Immunopositive
areas were extracted using specific protocols based on the color
parameters of hue, lightness, and saturation. The data are expressed as
ratios (%) of the extracted light green areas in the areas of thrombus
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were not different in patients with (n = 13) or without
heparin and/or thrombolytic therapy (n = 3).
Relationships between the time after onset and cellular
and molecular parameters
Table 1 shows the relationships between the time after
onset and cellular and molecular parameters. CD68- and
CD163-immunopositive cell numbers were positively
correlated with the time after onset, while the glyco-
phorin A-immunopositive area was negatively correlated
with the time after onset (Table 1, Fig. 5). There were no
significant correlations of the time after onset with gran-
ulocyte number, CD34-immunopositive area, and SMA-
immunopositive area.
Localization of CD163-positive cells in DVT
Double immunohistochemical staining showed colocali-
zation of CD68- and CD163-positive cells, accumulation
of CD163-positive cells in erythrocyte-rich areas, and
phagocytosis of erythrocyte fragments. Oval or stellate
CD163-positive cells were also accumulated in CD34-
and SMA-immunopositive areas (Fig. 6).
Discussion
The present study showed that the majority of macro-
phages expressed CD163 in aspirated thrombi from
patients with DVT and that CD163 macrophages were
closely distributed in erythrocyte-, CD34-, and SMA-
immunopositive cell-rich areas. Additionally, CD163
Fig. 3 Representative macro- and microscopic images of aspirated deep vein thrombi. a. Representative macroscopic image of an aspirated
thrombus. The aspirated thrombus is red or mixed red and white. b. Representative image of a fresh thrombus composed of erythrocyte-rich areas,
eosinophilic granular or fibrinous areas, and polymorphonuclear or mononuclear leukocytes. Neutrophils are mainly accumulated at the border of
the erythrocyte-rich and eosinophilic areas (9 days after onset). c. Representative image of lytic changes, including the loss of cellular morphology,
karyolysis, and karyorrhexis (9 days after onset). d. Representative image of macrophage-like cells (60 days after onset). e. Representative image of
an organizing reaction showing fibroblastic/myofibroblastic proliferation, leukocytic infiltration, and matrix deposition (33 days after onset).
Hematoxylin and eosin stain (b–d)
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macrophage or erythrocyte contents were positively or
negatively correlated with the time after onset.
The traditional view is that deep vein thrombi are
composed of erythrocytes with a large amount of fibrin
and relatively few platelets [11]. This view is based on
hematoxylin and eosin staining. Takahashi et al. [12]
immunohistochemically examined the attached por-
tions of deep vein thrombi in autopsy cases of venous
thromboembolism and found that fibrin and erythro-
cyte contents tended to exceed the platelet content.
However, there were no significant differences among
the contents in the thrombi. Fibrin, erythrocyte, and
platelet contents were consistently present in aspirated
thrombi, and the thrombi were rich in erythrocytes and
fibrin. These findings support the traditional view. Our
findings also suggested that thrombus content differed
in the portion of DVT, because aspirated thrombi were
mainly obtained from the proximal portion of the
thrombi. Additionally, we identified a time-dependent
change in erythrocyte content, but not fibrin and plate-
let contents, within 60 days after onset.
Monocytes/macrophages are cellular components of
venous thrombi. These cells appear around the edges of
ligation-induced thrombi and become evenly distributed
through the thrombi as resolution progresses in the rat
[13]. Macrophage content time-dependently increases in
experimental venous thrombi in the rat within 21 days
[13] and peak at 7 days in mice [14] and 14 days in rab-
bits [15]. The positive relationship between macrophage
content and the time after onset in aspirated thrombi is
compatible with that of experimental studies. This rela-
tionship suggests that the thrombus resolution process
is delayed in humans.
CD163 is a scavenger receptor for the hemoglobin–
haptoglobin (HbHp) complex in macrophages. Several
microenvironmental factors affect CD163 expression.
Interleukin (IL)-6, IL-10, and glucocorticoids upregulate
the expression of CD163 in monocytes/macrophages,
while tumor necrosis factor-α, IL-1β, interferon-γ, lipo-
polysaccharide, IL-4, IL-13, oxidative stress, and hypoxia
downregulate this expression [16]. High concentrations
of HbHp complex also induce CD163 expression with
an increase in secretion of IL-6 and IL-10 [17].
Hemoglobin that is released from lytic erythrocytes in
venous thrombi is likely to enhance HbHp complex for-
mation and upregulates CD163 expression in thrombus-
associated macrophages. Previous studies have suggested
Fig. 4 Representative immunohistochemical images of an aspirated deep vein thrombus. The thrombus is stained with hematoxylin and eosin
(HE) and antibodies for glycophorin A, integrin α2bβ3, and fibrin. The thrombus is rich in glycophorin A and fibrin
Table 1 Components of deep vein thrombi and their relationships






fibrin (%) 31 (24–41) −0.11 0.67
glycophorin A (%) 46 (34–49) −0.76 <0.001
integrin α2bβ3 (%) 14 (8–18) 0.04 0.89
CD34 (%) 0.06 (0.02–0.29) 0.35 0.18
SMA (%) 0.01 (0.001–0.07) 0.23 0.38
Granulocytes (/mm2) 204 (57–501) –0.18 0.49
CD68 (/mm2) 263 (122–460) 0.60 <0.05
CD163 (/mm2) 308 (221–553) 0.64 <0.01
CD206 (/mm2) 67 (30–92) 0.44 0.09
SMA smooth muscle actin
Data were analyzed using Spearman’s rank correlation coefficient
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a role for the binding of the HbHp complex to CD163 in
anti-inflammatory responses of macrophages [18]. Mac-
rophages in M2 or M2-like activation mode are related
to resolution of inflammation, tissue repair, and remod-
eling via anti-inflammatory cytokine and angiogenic fac-
tor production, and extracellular matrix digestion and
deposition [7]. Macrophages modulate the function and
growth of human mesenchymal stem cells [19]. There-
fore, interactions with endothelial cells, fibroblasts, and
tissue stem cells could be important components of the
role of macrophages in angiogenesis and tissue repair.
CD163 macrophages are frequently localized to areas
of interstitial fibrosis, collagen deposition, and accumu-
lation of SMA-positive myofibroblastic cells in chronic
kidney allograft injury [20]. The interactions between
endothelial cells, myofibroblasts/SMCs, and CD163
macrophages are not fully understood. However, ery-
throphagocytosis and the nearby distribution of CD163
macrophages, endothelial cells, and myofibroblasts/
SMCs suggest that CD163 macrophages play a role in
venous thrombus resolution/organization.
CD206 is known as a mannose receptor C type 1 that
recognizes sugars on microorganisms and some endogen-
ous glycoproteins. CD206 and CD163 are upregulated in
human atherosclerotic lesions with intraplaque hemor-
rhages [21]. However, CD206 expression is not prominent
in DVT. In contrast to CD163, CD206 is upregulated
by IL-4 and IL-13 [7]. These results suggest that there
are microenvironmental differences between thrombus
organization and hemorrhagic, atherosclerotic plaques.
There are small foci of CD34- and SMA-immunopositive
areas in nearly all thrombi. Experimental stasis-induced
venous thrombi have shown that microvessels or myofibro-
blasts and/or SMCs appear at 5 and 7 days, respectively,
and that these areas time-dependently increase [22]. Al-
though we observed a positive relationship between
CD34- and SMA-immunopositive areas, these positive
areas did not significantly correlate with the time after
onset. This discrepancy could be due to the dynamic
process of human DVT and the small foci of CD34-
and SMA-immunopositive areas (Table 1) of the aspi-
rated thrombi in this study.
There are several biomarkers for diagnosis of DVT,
active coagulation, and post-thrombotic syndrome. Be-
cause CD163 macrophage and erythrocyte contents were
positively or negatively correlated with the time after on-
set in our study, soluble CD163 (sCD163) and some
erythrocyte markers might predict acuity of DVT.
CD163 is shed from the macrophage surface into the cir-
culation as sCD163, and sCD163 levels increase during
inflammation and macrophage activation [23]. There-
fore, sCD163 could be a possible marker for evaluating
thrombus organization in patients with DVT without in-
flammatory diseases. Suades et al. [24] reported higher
erythrocyte (glycophorin A-positive)-derived microparti-
cle levels in acute coronary syndrome compared with
control subjects. Because the thrombus size in DVT is
larger than coronary thrombus size, glycophorin A-
positive microparticles could be a possible marker for
the acute phase of DVT.
Fig. 5 Relationships of the time after onset with CD68- and CD163-immunopositive cell numbers and glycophorin A-immunopositive areas
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This study has several limitations. We estimated the
time of onset based on clinical symptoms and a medical
interview. However, the onset of symptoms does not al-
ways indicate the onset of thrombus formation. This
discrepancy might affect quantification of immuno-
staining results. Our findings from aspirated thrombi
only represent a part of DVT. This could affect the
value of the immunopositive area, especially with CD34
and SMA. In our study, histological samples did not
provide information about the dynamic processes of
thrombus formation and thrombolysis. Immunopositive
areas and cell numbers were not different in patients
with or without heparin and/or thrombolytic therapy,
although we cannot deny β error due to the low power
in each group. Although the sample number was small,
the findings regarding aspirated thrombi from patients
with DVT are important for better understanding the
pathophysiology of DVT.
Conclusions
We histologically and immunohistochemically ana-
lyzed aspirated thrombi that were obtained from pa-
tients with DVT. Our study shows CD163- and
glycophorin A-immunopositive areas are positively or
negatively correlated with the time after onset. CD163
and erythrocyte contents and related products could
be markers for evaluating the age of DVT. CD163
macrophages might play a role in the organization
of DVT.
Additional file
Additional file 1: Additional movie file. Representative movie of X-ray
venography during thrombus aspiration. An aspiration catheter was
introduced in a thrombotic femoral vein and placed at the proximal
portion of the thrombus. The venous thrombus was aspirated under
negative pressure in a retrograde manner. (mp4 844 kb)
Fig. 6 Localization of CD163 in aspirated deep vein thrombi. Double immunohistochemical staining for CD68 and CD163 (upper panel), glycophorin
A and CD163 (middle panels), and CD163 and CD34 or SMA (lower panels). Expression of CD163 is visualized as a brown stain. Expression of CD68,
glycophorin A, CD34, and SMA are visualized as a red stain. Most of the CD163-immunopositive cells (brown) are immunopositive for CD68 (red) (upper
panel). CD163-immunopositive cells in erythrocyte-rich areas and phagocytosis of erythrocyte fragments can be seen (arrows, middle panels). Oval or
stellate CD163-immunopositive cells in CD34- and SMA-immunopositive organizing areas can be seen (lower panels)
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